《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：围手术期甲状旁腺功能的评估、处理及术后TSH抑制的精准个体化管理

doi:10.19401/j.cnki.1007-3639.2025.09.004

摘要/Abstract

摘要：

近年来，分化型甲状腺癌（differentiated thyroid cancer，DTC）的发病率持续上升，其围手术期管理和术后促甲状腺激素（thyroid-stimulating hormone，TSH）抑制治疗策略备受关注。2025年美国甲状腺学会（American Thyroid Association，ATA）发布了《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》，在围手术期甲状旁腺功能保护和TSH抑制治疗方面有重要更新。2025版ATA指南推荐术中应用新方法识别并保护甲状旁腺，甲状腺全切术后采用基于甲状旁腺激素（parathyroid hormone，PTH）指导的钙剂和维生素D补充方案。TSH抑制治疗方面，2025版ATA指南取消初治期具体TSH目标值推荐，强调应根据患者初始复发风险和治疗反应动态调整TSH目标，实现个体化管理，避免过度治疗。

关键词: 分化型甲状腺癌, 围手术期, 甲状旁腺功能, 促甲状腺激素抑制, 个体化管理

Abstract:

In recent years, the incidence of differentiated thyroid cancer (DTC) continues to rise, with increasing attention to perioperative management and postoperative thyroid-stimulating hormone (TSH) suppression therapy strategies. The American Thyroid Association (ATA) released the “2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer” in 2025, which include significant updates on perioperative parathyroid function protection and TSH suppression therapy. In terms of perioperative management, the 2025 ATA guidelines recommend intraoperative application of novel methods to identify and protect the parathyroid glands, and adoption of parathyroid hormone (PTH)-guided calcium and vitamin D supplementation protocols following total thyroidectomy. Regarding TSH suppression therapy, the 2025 ATA guidelines eliminate specific TSH target value recommendations for initial treatment, emphasizing that TSH targets should be dynamically adjusted based on patients’ initial recurrence risk and treatment response to achieve individualized management and avoid overtreatment.

Key words: Differentiated thyroid cancer, Perioperative period, Parathyroid function, Thyroid-stimulating hormone suppression, Individualized management

中图分类号:

R736.1

伍一鸣, 冯楚瑶, 高莹, 武晓泓. 《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：围手术期甲状旁腺功能的评估、处理及术后TSH抑制的精准个体化管理[J]. 中国癌症杂志, 2025, 35(9): 841-849.

WU Yiming, FENG Chuyao, GAO Ying, WU Xiaohong. Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: perioperative assessment and management of parathyroid function and precision individualized management of postoperative TSH suppression in adults with differentiated thyroid cancer[J]. China Oncology, 2025, 35(9): 841-849.

图/表 3

表1

表2

表3

参考文献 38

[1]	RINGEL M D, SOSA J A, BALOCH Z, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer[J]. Thyroid, 2025, 35(8): 841-985.
[2]	JHA S, SIMONDS W F. Molecular and clinical spectrum of primary hyperparathyroidism[J]. Endocr Rev, 2023, 44(5): 779-818.
[3]	PRADHAN R, AGARWAL A, LOMBARDI C P, et al. Applied embryology of the thyroid and parathyroid glands[M]// Surgery of the Thyroid and Parathyroid Glands. Amsterdam: Elsevier, 2021: 15-25. e4.
[4]	WANG Z L, LUO B M, CHEN W, et al. Chinese Association of Ultrasound in Medicine and Engineering, superficial organs and peripheral vessels committee expert consensus on selected common clinical issues in parathyroid ultrasound (2024 edition)[J]. Ultrasound Med Biol, 2025, 51(6): 1008-1017.
[5]	MELOT C, DENIZIAUT G, MENEGAUX F, et al. Incidental parathyroidectomy during total thyroidectomy and functional parathyroid preservation: a retrospective cohort study[J]. BMC Surg, 2023, 23(1): 269.
[6]	ÖZDEN S, ERDOĞAN A, SIMSEK B, et al. Clinical course of incidental parathyroidectomy: single center experience[J]. Auris Nasus Larynx, 2018, 45(3): 574-577. doi: S0385-8146(17)30435-2 pmid: 28807528
[7]	FEWINS J, SIMPSON C B, MILLER F R. Complications of thyroid and parathyroid surgery[J]. Otolaryngol Clin North Am, 2003, 36(1): 189-206, x.
[8]	李治, 刘春萍, 石岚, 等. 546例分化型甲状腺癌手术治疗分析[J]. 中华外科杂志, 2008, 46(5): 375-377.
	LI Z, LIU C P, SHI L, et al. Analysis of surgical treatment of 546 cases of differentiated thyroid cancer[J]. Chin J Surg, 2008, 46(5): 375-377.
[9]	GIORDANO D, VALCAVI R, THOMPSON G B, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature[J]. Thyroid, 2012, 22(9): 911-917. doi: 10.1089/thy.2012.0011 pmid: 22827494
[10]	HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133. doi: 10.1089/thy.2015.0020 pmid: 26462967
[11]	BARBIERI D, INDELICATO P, VINCIGUERRA A, et al. Autofluorescence and indocyanine green in thyroid surgery: a systematic review and meta-analysis[J]. Laryngoscope, 2021, 131(7): 1683-1692.
[12]	中华人民共和国国家卫生健康委员会. 关于印发原发性肺癌等18个肿瘤诊疗规范(2018年版)的通知[Z]. 2018. https://www.nhc.gov.cn/yzygj/c100068/201812/a7f5161869164dbb879df3782a144aec.shtml.
	National Health Commission of the People’s Republic of China. Notice on issuing the standards for diagnosis and treatment of 18 cancers including primary lung cancer (2018 edition)[Z]. 2018. https://www.nhc.gov.cn/yzygj/c100068/201812/a7f5161869164dbb879df3782a144aec.shtml.
[13]	PATEL K N, YIP L, LUBITZ C C, et al. The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults[J]. Ann Surg, 2020, 271(3): e21-e93.
[14]	LI Z, FEI Y, LI Z H, et al. Outcome of parathyroid function after total thyroidectomy when calcium supplementation is administered routinely versus exclusively to symptomatic patients: a prospective randomized clinical trial[J]. Endocrine, 2022, 75(2): 583-592.
[15]	BOLLERSLEV J, REJNMARK L, ZAHN A, et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders[J]. Eur J Endocrinol, 2022, 186(2): R33-R63.
[16]	中华医学会内分泌学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会核医学分会, 等. 中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J]. 中华内分泌代谢杂志, 2022, 38(8): 700-748.
	Chinese Society of Endocrinology, Chinese Endocrinologist Association, Chinese Society of Nuclear Medicine, et al. Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Chin J Endocrinol Metab, 2022, 38(8): 700-748.
[17]	HAYMART M R, ESFANDIARI N H, STANG M T, et al. Controversies in the management of low-risk differentiated thyroid cancer[J]. Endocr Rev, 2017, 38(4): 351-378. doi: 10.1210/er.2017-00067 pmid: 28633444
[18]	COOPER D S, DOHERTY G M, HAUGEN B R, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2006: 060118075408001.
[19]	COOPER D S, DOHERTY G M, HAUGEN B R, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11): 1167-1214. doi: 10.1089/thy.2009.0110 pmid: 19860577
[20]	FILETTI S, DURANTE C, HARTL D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(12): 1856-1883. doi: S0923-7534(20)32555-2 pmid: 31987292
[21]	中华医学会内分泌学分会, 中华医学会外科学分会甲状腺及代谢外科学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J]. 中华内分泌代谢杂志, 2023, 39(3): 181-226.
	Chinese Society of Endocrinology, Thyroid and Metabolism Surgery Group of the Chinese Society of Surgery, Chinese Association of Head and Neck Oncology of China Anti-Cancer Association, et al. Guidelines for the diagnosis and management of thyroid nodules and differentiated thyroid cancer (second edition)[J]. Chin J Endocrinol Metab, 2023, 39(3): 181-226.
[22]	HOVENS G C, STOKKEL M P, KIEVIT J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2007, 92(7): 2610-2615.
[23]	PUJOL P, DAURES J P, NSAKALA N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 1996, 81(12): 4318-4323.
[24]	MCGRIFF N J, CSAKO G, GOURGIOTIS L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer[J]. Ann Med, 2002, 34(7/8): 554-564.
[25]	CARHILL A A, LITOFSKY D R, ROSS D S, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012[J]. J Clin Endocrinol Metab, 2015, 100(9): 3270-3279. doi: 10.1210/JC.2015-1346 pmid: 26171797
[26]	DIESSL S, HOLZBERGER B, MÄDER U, et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma[J]. Clin Endocrinol, 2012, 76(4): 586-592.
[27]	KLUBO-GWIEZDZINSKA J, AUH S, GERSHENGORN M, et al. Association of thyrotropin suppression with survival outcomes in patients with intermediate- and high-risk differentiated thyroid cancer[J]. JAMA Netw Open, 2019, 2(2): e187754.
[28]	TIAN T, HUANG R, LIU B. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment[J]. Endocrine, 2019, 65(1): 149-154.
[29]	SUGITANI I, FUJIMOTO Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma: a randomized controlled trial[J]. J Clin Endocrinol Metab, 2010, 95(10): 4576-4583.
[30]	LEE M C, KIM M J, CHOI H S, et al. Postoperative thyroid-stimulating hormone levels did not affect recurrence after thyroid lobectomy in patients with papillary thyroid cancer[J]. Endocrinol Metab, 2019, 34(2): 150-157.
[31]	XU S Y, HUANG Y, HUANG H, et al. Optimal serum thyrotropin level for patients with papillary thyroid carcinoma after lobectomy[J]. Thyroid, 2022, 32(2): 138-144.
[32]	GUBBI S, AL-JUNDI M, FOERSTER P, et al. The effect of thyrotropin suppression on survival outcomes in patients with differentiated thyroid cancer: a systematic review and meta-analysis[J]. Thyroid, 2024, 34(6): 674-686. doi: 10.1089/thy.2023.0711 pmid: 38717947
[33]	PARK J H, LEE Y M, LEE Y H, et al. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma[J]. J Surg Oncol, 2018, 118(3): 390-396. doi: 10.1002/jso.25164 pmid: 30114333
[34]	SUGITANI I, ITO Y, TAKEUCHI D, et al. Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan association of endocrine surgery task force on management for papillary thyroid microcarcinoma[J]. Thyroid, 2021, 31(2): 183-192. doi: 10.1089/thy.2020.0330 pmid: 33023426
[35]	SUGITANI I, FUJIMOTO Y, YAMADA K. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma[J]. World J Surg, 2014, 38(3): 673-678. pmid: 24233662
[36]	KIM H I, JIN M H, KO N G, et al. Effect of TSH levels during active surveillance of PTMC according to age[J]. Endocr Relat Cancer, 2022, 29(4): 191-200.
[37]	LEE J Y, KIM J H, KIM Y K, et al. US predictors of papillary thyroid microcarcinoma progression at active surveillance[J]. Radiology, 2023, 309(1): e230006.
[38]	YAMAMOTO M, MIYAUCHI A, ITO Y, et al. Active surveillance outcomes of patients with low-risk papillary thyroid microcarcinoma according to levothyroxine treatment status[J]. Thyroid, 2023, 33(10): 1182-1189. doi: 10.1089/thy.2023.0046 pmid: 37310904

Clinical study	Case, N	Follow-up/year	Main result	Benefit or not
Hovens, 2007^[22]	366	8.85	There is a positive correlation between serum TSH levels and the risk of recurrence and cancer-related mortality. A TSH level exceeding 2 mU/L significantly increases the risk of tumor progression, recurrence, and death	Yes
Pujol, 1996^[23]	141	7.9	Patients with sustained TSH suppression (≤0.05 mU/L) exhibit significantly longer recurrence-free survival compared to those with consistently elevated TSH (≥1 mU/L). Moreover, the degree of TSH suppression is an independent predictor of recurrence in multivariate analysis	Yes
McGriff, 2002^[24]	4 147	4.5-19.5	TSH suppression (maintaining TSH <0.4-0.5 mU/L) significantly reduces the incidence of major adverse clinical events, including disease progression, recurrence, or death	Yes
Carhill, 2015^[25]	3 238	6	Moderate TSH suppression (below the normal range) improves overall survival and disease-free survival across all disease stages. However, further suppression to undetectable levels does not provide additional clinical benefits	Yes
Diessl, 2012^[26]	157	8	Compared to the non-suppressed group, patients with a median TSH level ≤0.1 mU/L show significantly longer thyroid cancer-specific survival. Nonetheless, further suppression to <0.03 mU/L yields no additional survival advantage over ≤0.1 mU/L	Yes
Klubo, 2019^[27]	867	7.2	TSH suppression therapy did not improve 5-year progression-free survival in certain patient cohorts	Not
Tian, 2019^[28]	166	5-9	In intermediate- to high-risk DTC patients with pre-ablation Tg<1 ng/mL, no significant difference in tumor recurrence was observed across TSH groups (<0.1, 0.1-0.5, 0.5-2.0 or >2.0 mU/L)	Not

Clinical study	Case, N	Follow-up/year	Main result	Benefit or not
Sugitani, 2010^[29]	433	7	No significant difference in disease-free survival was observed between the group with TSH suppressed to <0.01 mU/L and the group maintaining TSH within the normal range of 0.4-5.0 mU/L	Not
Lee, 2019^[30]	1 528	5.6	In low-risk patients who underwent lobectomy, the recurrence rate was only 1.4% during a median follow-up of 5.6 years. Furthermore, no statistically significant difference in recurrence rate was found among groups with different TSH levels (<0.5, 0.5-1.9, 2.0-4.4 or >4.5 mU/L)	Not
Xu, 2021^[31]	2 297	5.8	The study cohort consisted of 41.2% low-risk, 42.4% intermediate-risk, and 16.4% high-risk patients. The results indicated that for the entire patient population, the median TSH level was not associated with the risk of recurrence. However, in the intermediate- to high-risk subgroup, recurrence-free survival was significantly higher when the median TSH was controlled between 0.6-2.0 mU/L compared to levels >4.0 mU/L	Partial benefit in a subgroup
Gubbi, 2024^[32]	3 591	5	For intermediate- and high-risk DTC patients, no significant differences were found in progression-free survival, disease-free survival, or recurrence-free survival between the TSH-suppressed group and the non-suppressed group. Moreover, TSH suppression may increase the risk of secondary complications	Not
Park, 2018^[33]	1 047	8.9	The structural recurrence rate after lobectomy for low- to intermediate-risk PTC was 4.0%. The serum TSH level at 1 year post-operation was an independent risk factor for recurrence, with patients having TSH>1.85 mU/L demonstrating a significantly higher recurrence rate	Yes

Clinical study	Case, N	Follow-up/year	Main result	Benefit or not
Sugitani, 2014^[35]	322	6.5	No significant correlation was observed between the mean TSH level and tumor growth	Not
Kim, 2022^[36]	234	55.6	When using the time-weighted average (TW)-TSH, a high TW-TSH was found to be closely associated with PTMC progression. Specifically, for patients under 50 years of age, a TW-TSH level >1.74 mU/L was identified as an independent risk factor for disease progression	Yes
Lee, 2023^[37]	699	4	A baseline serum TSH level ≥7 mU/mL may predict tumor progression	Yes
Yamamoto, 2023^[38]	2 509	10	Patients receiving LT4 treatment showed a significantly reduced tumor volume doubling rate, suggesting that TSH suppression may delay the growth of PTMC	Yes